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CHAPTER 3 | PART ONE
FROM PREECLAMPSIA TO RENAL 
DISEASE: A ROLE OF ANGIOGENIC 
FACTORS AND THE RENIN-ANGIOTENSIN 
ALDOSTERONE SYSTEM? 
Tsjitske J. Toering
Anne Marijn van der Graaf  
Marijke M. Faas
A. Titia Lely




Complicating up to 8% of pregnancies, preeclampsia is the most common glomerular 
disease worldwide and remains a leading cause of infant and maternal morbidity 
and mortality. Although, the exact pathogenesis of this syndrome of hypertension 
and proteinuria is still incomplete, a consistent line of evidence has identified 
an imbalance of proangiogenic and antiangiogenic proteins as a key factor in the 
development of preeclampsia.1-3 Furthermore, recently, more attention has turned to 
the renin-angiotensin aldosterone system (RAAS) to provide understanding for the 
hypertension of preeclampsia.4 The imbalance of the RAAS and imbalance between 
angiogenic and anti-angiogenic factors, which may be both common to preeclampsia 
and chronic kidney disease (CKD), might explain why a history of preeclampsia 
predisposes women to develop CKD.
 In this review, we briefly describe the characteristics of preeclampsia 
with a focus on the mechanisms of angiogenesis and the RAAS and its role in the 
pathogenesis of preeclampsia. Our main focus will be on the intriguing association 
between preeclampsia and the subsequent increased risk of developing CKD and on 




The diagnosis of preeclampsia is clinical. As defined by the International Society 
of Studies of Hypertension in Pregnancy, the diagnosis requires blood pressures of 
140/90 mmHg or higher on two occasions combined with urinary protein excretion of 
≥300mg/day.5 Laboratory tests, such as liver function tests, quantification of urinary 
protein, or serum creatinine may be helpful in characterizing the degree of end-organ 
damage, but none is specific for preeclampsia.6
 In the pathogenesis of preeclampsia, the placenta is the central organ 
since removal of the placenta abolishes the disease.7 Pathological examination 
reveals several abnormalities including infarcts, atherosis, thrombosis, and chronic 
inflammation.8 During normal placentation, the embryo-derived cytotrophoblast cells 
invade the maternal spiral arteries. As part of this process, the cytotrophoblasts adopt 
an endothelial phenotype.7,9 In preeclampsia, the invasion of the cytotrophoblasts into 
the spiral arteries is incomplete; they are only present in the superficial layers of the 
decidua. The abnormal placentation is thought to lead to release of secreted factors 




Renal function undergoes physiological adaptations in pregnancy. Healthy pregnant 
women show marked glomerular hyperfiltration by 40 to 60% in the second half of 
pregnancy.10 This hyperfiltration appears to result primarily from depression of the 
oncotic pressure.10 Furthermore, an increased rate of effective renal plasma flow 
(ERPF) is found during pregnancy, (approximately 80% by 12 weeks' gestation).10 In 
contrast, during preeclampsia these functional changes in renal hemodynamics are 
different. The GFR in women with preeclampsia is significantly lower as compared with 
healthy gravid control subjects (91 ml/min per 1.73 m2 vs 149 ml/min per 1.73 m2). Of 
interest, no differences were found in ERPF between women with preeclampsia and 
healthy controls.11 
 This depression in GFR during preeclampsia coincides with typical 
histopathological changes in the kidney, called glomerular endotheliosis, which 
is characterized by fibrin deposition, endothelial swelling and loss of capillary 
space.12 Although these renal histological changes have been considered 
pathognomonic for preeclampsia, this may not be the case. Several groups have 
performed antenatal renal biopsies in normal pregnant women and women with 
gestational hypertension. For instance, Strevenset al. demonstrated that five 
of twelve normal pregnant women had, albeit very mild, evidence of glomerular 
endotheliosis.3 These endotheliosis lesions resolve at variable rates postpartum, 
but it has been proposed that the characteristic renal changes of preeclampsia can 
be more long-standing.13 The mechanism for hypofiltration during preeclampsia is 
not elucidated; both (renal) hemodynamic mechanisms and secondary changes to 
structural renal changes are proposed.4 Lately, podocyte alterations and podocyturia 
have been described during preeclampsia.14 Proteinuria in patients with preeclampsia 
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might not only be mediated by endothelial alterations described classically, but also 
by disturbances of podocyte biology including impaired survival, enhanced apoptosis 
and down-regulation of nephrin and other key proteins of the slit diaphragm.15
 
Angiogenic factors
Recent observations support the hypothesis that altered expression of placental 
anti-angiogenic factors are partially responsible for the clinical manifestations of 
preeclampsia. Soluble Fms-like tyrosine kinase-1 (sFlt1, the soluble form of vascular 
endothelial growth factor (VEGF) receptor 1) and placenta-derived soluble TGF-B co-
receptor endoglin (sEng), secreted by the placenta, are increased in the maternal 
circulation weeks before the onset of preeclampsia.3 These elevated factors might 
lead to endothelial dysfunction and therefore decreased endothelium dependent 
vasodilation and proteinuria. Several days after delivery, sFlt1 levels normalize 
coinciding with decrease in proteinuria and blood pressure. The fact that increasing 
circulating sFlt1 levels in gravid mice and rats, either by direct infusion of the 
protein or by injecting adenovirus expressing the sFlt1 mRNA, produces a syndrome 
resembling human preeclampsia, including hypertension, proteinuria and glomerular 
endotheliosis, suggests that sFlt1 plays a role in the pathogenesis of preeclampsia.1,16 
 The exact mechanism by which (anti)-angiogenic factors are involved in 
the development of the typical renal phenotype during preeclampsia is unknown. 
However, recent evidence shows that VEGF and its type 2 receptor have a clear role 
in the podocyte and slit diaphragm.17 Overexpression of VEGF-A induces glomerular 
diseases.18 VEGF produced by the podocyte regulates the structure and function of the 
adjacent endothelial cell. 
 
Renin-angiotensin aldosterone system
In normal pregnancy there are marked changes in the RAAS including considerably 
elevated angiotensin II (ang II) levels.16 However, vascular resistance decreases 
markedly during normal pregnancy, suggesting that pregnant individuals are less 
sensitive to ang II than non-pregnant individuals.19,20 In contrast, during preeclampsia 
decreased circulating components of the RAAS with enhanced sensitivity to ang II 
infusion have been reported.5,20,21
 There are several possible explanations for this enhanced sensitivity of ang II 
infusion. Firstly, it may be mediated through increased placental ang II type 1 receptor 
(AT1-R) expression, which has been specifically observed to be upregulated on the 
decidual or maternal side of the placenta.22 Secondly, angiotensin 1-7 (ang 1-7), a 
counterregulator of ang II, is decreased during preeclampsia compared with normal 
pregnancy. Therefore, this decreased ang 1-7 in these women may play a role in the 
hypertension seen in these patients.23 A third explanation is that circulating ang II 
type 1 receptor autoantibodies (AT1-AA) levels are elevated, which may explain the 
hypersensitivity to the effects of ang II.24 After injecting AT1-AA into pregnant mice 
and rats, hypertension, proteinuria, glomerular endothelial damage, and elevated 
levels of anti-angiogenic factors can be seen, suggesting that AT1-AA contribute to the 
pathogenesis of preeclampsia.25,26
45
However, in humans, increases in AT1-AA are not specifically related to preeclampsia, 
as this autoantibody is also elevated during intra-uterine growth restriction without 
preeclampsia.27 Therefore, the AT1-AA could be more related to impairment in placental 
development (placental ischemia) rather than mediating the preeclamptic phenotype. 
This is enforced by the fact that the disappearance of clinical symptoms do not require 
the loss of the autoantibody.28 
 
Interaction between sFlt1 and RAAS 
So far, most studies on preeclampsia have focused on angiogenic factors or on the 
RAAS, and not on the combination of both and the interaction between the two. Below, 
we will point out some evidence of interaction between sFlt1 and the RAAS. 
 A link between AT1-AA and angiogenic factors has been made by Zhou 
et al.29; circulating AT1-AA and ang II are capable of inducing sFlt1 production via AT1-R 
activation and downstream calcineurin/nuclear factor of activated T-cells signaling. 
Therefore, both may be responsible for placental sFlt1 up-regulation in preeclampsia. 
These observations extend a previous finding from the same group that ang II 
stimulates sFlt1 production in placental explants.30 Moreover, Kim et al. have shown 
that in human proximal tubule cells, ang II induces an increased sFlt1 production cells, 
which is significantly blocked by losartan.31 
 Furthermore, in pregnant mice, injection of serum from preeclamptic women 
with AT1-AA increases the sFlt1 concentrations via the AT1-R significantly as compared 
to pregnant mice injected with serum from normotensive pregnant women.29 Moreover, 
another study in mice shows that the AT1-AA induced hypertension, proteinuria and 
renal abnormalities is reduced by co-injection with losartan or infusion of VEGF121.32 
In contrast, in the transgenic renin overexpression preeclampsia rat model, in which 
AT1-AA is elevated, no increase in sFlt1 concentration was found.33 
 Whether a similar relation between AT1-AA and sFlt1 also exist in human 
pregnancy is unclear. In preeclamptic patients, some studies show no correlation 
between sFlt1 and AT1-AAs,34,35 while another study shows the titer of AT1-AA, is 
significantly correlated with sFlt1 level in severe preeclamptic women.36
 In conclusion, although the exact interaction between the RAAS and sFlt is 
still unknown (especially in humans), the studies described above suggest that during 
preeclampsia the impairment in the RAAS may influence the sFlt1 production. 
AFTER PREECLAMPSIA
Long-term vascular risk after preeclampsia 
Long term vascular risk following a preeclamptic pregnancy has been recognized 
for many years. Already in the 1960s36 it was shown that a history of preeclampsia 
increases the risk of future hypertension. A meta-analysis showed that 1885 of 
3658 formerly preeclamptic women developed chronic hypertension in a follow-up 
time of 5-32 years. Therefore, the relative risk of a later diagnosis of hypertension in 
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formerly preeclamptic women is 3.7.37 Not only the risk for hypertension is increased 
in formerly preeclamptic women, they also have a higher risk for hypertension related 
diseases, i.e. ischaemic heart disease, in the next 15-19 years.38 Furthermore, another 
meta-analysis concluded that formerly preeclamptic women have an approximately 
double risk of early cardiac, cerebrovascular, and peripheral arterial disease, and 
cardiovascular mortality.39
 
Kidney Disease after Preeclampsia
Preeclampsia is more common in women with an underlying kidney disease. On the 
other hand, it has been suggested that preeclampsia itself increases the risk of kidney 
disease later in life. From the early 1960s till 1980s, several renal biopsy studies 
discussed the appearance of renal damage in women who had a pregnancy affected 
by preeclampsia. Zech et al. have studied the appearance of renal injury in biopsies 
three months to four years after pregnancy in a series of sixty formerly preeclamptic 
women. In many cases, typical glomerular lesions disappeared rapidly within six 
months. However, vascular lesions remained the same or changed only very slowly. 
Furthermore, these vascular lesions were directly related with an increased blood 
pressure.40 
 Although nowadays, postpartum renal biopsy studies in formerly 
preeclamptic women are uncommon, a recent large cohort study has shown that 
a history of preeclampsia is a risk factor for undergoing a kidney biopsy later in 
life.41 In a cohort of 756,420 women, the relative risk of undergoing a kidney biopsy was 
significantly higher in women with a history of preeclampsia (RR of 12 (95% CI 6.3 to 
23)). Subsequently, in another large cohort of 570,433 women, Vikse et al. studied the 
risk of developing end stage renal disease (ESRD) after preeclampsia.42 Preeclampsia 
during the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% 
CI 3.6 to 6.1). Moreover, if women also had preeclampsia during subsequent pregnancies 
the relative risk of ESRD was even higher (15.5 95% CI 7.8 to 30.8). According to the 
authors, the association was stronger in preeclamptic women who had given birth to 
preterm infant or child with low birth weight, which might suggest that women with 
severe, early-onset preeclampsia have a higher risk for developing ESRD. 
 
Microalbuminuria after preeclampsia
A recent meta-analysis concluded that 31% of formerly preeclamptic women had 
microalbuminuria compared with 7% of women with uncomplicated pregnancies on 
average 7.1 years postpartum. This prevalence is similar to that found in patients with 
type 1 diabetes mellitus (28% at 14 years after diagnosis).43 Furthermore, women 
have a 4-fold increased risk of microalbuminuria after mild preeclampsia, and a 8-fold 
increased risk after severe preeclampsia, suggesting a graded relationship according 
to severity of the preeclamptic episode.43 The high incidence of microalbuminuria 
in formerly preeclamptic women found in the meta-analysis might partly be caused 
by the inclusion of a study that examined women with diabetes mellitus type 1.44 
Especially since diabetic nephropathy, which is present in 41.9% of the formerly 
preeclamptic women with diabetes, is associated with elevated blood pressure 
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and endothelial dysfunction. Still, the finding that almost one-third of formerly 
preeclamptic women have microalbuminuria is important given the associated risks 
of ESRD and cardiovascular disease. Several factors may explain the increased risk 
of microalbuminuria in formerly preeclamptic women: undetected hypertension and 
microalbuminaria before pregnancy, shared risk factors for preeclampsia and kidney 
disease and the fact that preeclampsia itself may damage the kidneys with scarring 
or incomplete healing from the endotheliosis. A potential mechanism of long-term 
renal damage might be that renal damage during preeclampsia results in epigenetic 
changes, and therefore leading to permanent kidney damage. It would be interesting 
to unravel the role of epigenetic changes in the development of kidney damage after 
preeclampsia.
 
Renal function parameters after preeclampsia
Although several studies, as described above, have found persistent microalbuminuria 
in formerly preeclamptic women several years after pregnancy, no differences were 
found in serum renal function parameters in formerly preeclamptic women.43 None 
of these studies have shown a significant difference in serum creatinine values or 
creatinine clearance between formerly preeclamptic women and healthy parous 
controls. However, when looking at particular characteristics of renal function and 
performing renal function measurements in a more accurate way, abnormalities in 
renal function in formerly preeclamptic women can be seen.
 In 1998, van Beek et al. examined renal hemodynamic values (ERPF and GFR) 
at least four months postpartum in primiparous formerly preeclamptic women and 
healthy parous controls.45 These renal hemodynamic values were derived from the 
continuous infusion of para-aminohippurate and inulin. Although, GFR did not differ 
significantly between the groups, ERPF appeared to be significantly lower in formerly 
preeclamptic women (482 ± 88 vs 553 ± 67 ml/min/1.73 m2). Consequently, filtration 
fraction (FF) was significantly higher in formerly preeclamptic women (0.28% ± 0.04% 
vs 0.22% ± 0.03%). Likewise, renal vascular resistance (RVR) was also higher.
 More recently, Spaan et al. compared in a similar protocol formerly preeclamptic 
women with parous controls at least 20 years after pregnancy.46 They also found a 
significant difference in ERPF (399 ± 61 vs 463 ± 83 mL/min/1.73 m2 former preeclamptic 
women vs controls respectively) and RVR (122 ± 28 vs 95 ± 20). Furthermore, creatinine 
clearance appeared to be significantly lower in formerly preeclamptic women (88 ± 15 
vs 100 ± 19 mL/min/1.73m2). 
 According to these results, we can conclude that women who suffered from 
preeclampsia have abnormalities in renal function later in life. Both after short- and 
long-term follow-up an increased RVR and a reduced ERPF is observed, which supports 
the idea that renal vasoconstriction might play a central role in the development of 
hypertension and renal impairment in formerly preeclamptic women. 
 
Renin-angiotensin aldosterone system after preeclampsia
During preeclampsia the plasma levels of ang II are decreased, while the sensitivity for 
ang II is increased.5,20-22 In most cases, circulating ang II levels normalize within three 
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months after delivery.5,20-22 However, in one study, upregulation of ang II was found 
in hypertensive subgroups of formerly preeclamptic women.5,20-22 Although there is 
no clear difference between formerly preeclamptic women and healthy controls in 
circulating ang II levels, several studies have suggested a difference in ang II sensitivity.
 Three studies have examined the ang II sensitivity in formerly preeclamptic 
women.47-49 One study showed no difference in blood pressure response to ang II 
between formerly preeclamptic women and healthy controls.50 However, the two 
other studies conducted ang II infusion both during low and high sodium diet, and 
showed increased blood pressure responsiveness to ang II during low sodium intake 
in women with a history of gestational hypertension or preeclampsia.47,49 Furthermore, 
Hladunewich et al. have shown that after stimulating the RAAS with lower-body 
negative pressure, a delayed increase in circulating RAAS components was found in 
formerly preeclamptic women.49
 Differences in results in the studies mentioned above can be explained by 
the use of different doses of ang II, whether or not using a standardized sodium diet 
and studying patients at different periods of the menstrual cycle.51 Sodium intake is of 
major influence on the RAAS and ang II sensitivity, since, low sodium diet is a strong 
activator of the RAAS. From the above studies it seems that there are differences in the 
function of the RAAS in formerly preeclamptic women as compared with women who 
experienced a normal pregnancy. However, this may only be revealed under certain 
circumstances, such as under low salt diet. In this respect it is of interest to mention 
that after pregnancy complicated by hypertension increased pressor response to a high 
sodium diet, e.g. sodium sensitivity is reported.47 This increased sodium sensitivity 
could lead to renal disease on the long term. 
 As mentioned above, a different expression of AT1-R may be involved in 
the enhanced ang II sensitivity found in formerly preeclamptic women. However, 
Hladunewich et al. could not show differences in AT1-R mRNA expression on tissue level 
in skin biopsies.49 Another explanation for the enhanced ang II sensitivity is elevation 
of AT1-AA levels in formerly preeclamptic women. Although AT1-AA levels decline by 
50% at one week after delivery, Hubel et al. concluded that significantly more formerly 
preeclamptic women were characterized by the presence of AT1-AA as compared to 
healthy controls (17.2% vs 2.9%).52 Because ang II increases sFlt1 production in the 
human proximal tubule cell, the existence of AT1-AA and increased levels of sFlt1 may 
be linked.53 
 Concerning other RAAS parameters, no differences in plasma renin 
concentration and plasma aldosterone concentrations were found between former 
preeclamptic women and control pregnancies at least four months postpartum.45,48,54,55 
However, in response to ang II infusion, aldosterone levels in women with a history of 
new-onset hypertension during pregnancy are significantly increased as compared to 
normotensive controls.47 Another study could not confirm this increased aldosterone 
response.48 Again, the difference in results might be explained by the differences in 




Even though sFlt1 levels rapidly decrease during the first week after delivery, indicating 
that the large fraction of sFlt1 is derived from the placenta, increased levels of sFlt1 
have been found in formerly preeclamptic women.52,56,57 This persistence of increased 
levels of sFlt1 in formerly preeclamptic women might be due to a richer extra-placental 
source of sFlt1 in these women, such as endothelial cells and monocytes. Indeed, one 
year postpartum, formerly preeclamptic women showed increased expression of sFlt1 
in peripheral blood mononuclear cells.58 This increased sFlt1 may lead to changes 
in the vascular endothelium which may increase the risk of reno-vascular diseases 
in later life. Interestingly, patients with CKD and decreased GFR without a history of 
preeclampsia present with increased plasma levels of sFlt1, which correlates positively 
with proteinuria.59
 However, other studies did not find a significant difference in baseline sFlt1 
levels between women with a history of new-onset hypertension in pregnancy and 
women with a history of normotensive pregnancies.2,47,60,61 Interestingly, in one of 
these studies it is shown that during low-sodium balance, women with a history of 
gestational hypertension had greater sFlt1 response to ang II compared to women 
with a history of normotensive pregnancy.47 This not only reinforces an interaction 
between the RAAS and sFlt1, as described above, but also shows that it is important 
to take sodium status into account when studying the interaction between RAAS and 
angiogenic factors. It also shows that sodium intake could be a factor of influence in the 
discrepancy between the human studies on the relationship between AT1-AA and sFlt1 
as described above. This interaction between sFlt1 and the RAAS after preeclampsia 
is interesting and should be elucidated in future studies.
 
CONCLUSIVE REMARKS
In summary, preeclampsia is a risk factor for the development of CKD. Why 
preeclampsia is associated with an increased risk for developing kidney disease is still 
unclear. One possibility could be that both preeclampsia and CKD are caused by the 
same risk factors (such as hypertension, obesity, insulin resistance, and endothelial 
dysfunction). Furthermore, the role of angiogenic factors (sFlt1) and the RAAS (AT1-
AA and up-regulation of AT1-R) in the pathophysiology of both preeclampsia and CKD 
reinforces the described association. In regards to well-known cardiovascular risk 
factors, Romundstad et al have shown that approximately 50% of the elevated risk for 
future hypertension after preeclampsia can be explained by preexisting risk factors.62 
Therefore, as it has been described by Sattar et al., pregnancy might be a stress test 
that can reveal subclinical cardiovascular and renal disease.63 
 Moreover, preeclampsia itself induces deleterious effects to the kidney, 
revealed by persistent microalbuminuria in a subset of formerly preeclamptic women. 
As described above, during preeclampsia and still after preeclampsia, women 
have a disturbance in their regulation of the RAAS (increased sensitivity for angII, 
possible by up-regulation of the AT1-R and increased AT1-AA). This might induce 
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persistent increased ang II sensitivity, increased salt sensitivity and altered renal 
hemodynamics. In addition, preeclampsia induced endothelial dysfunction appears 
to remain after preeclampsia in a lot of patients64 and is an independent risk factor 
for future cardiovascular and renal health. The reason for the remaining endothelial 
dysfunction is unknown, it may, however, be suggested that preeclampsia induces 
epigenetic changes in endothelial cells. Endothelial cell dysfunction may also be 
enhanced by increased levels of sFlt1 in formerly preeclamptic women. Ultimately, 
these disturbances in formerly preeclamptic women lead to an increased risk for CKD 
(figure 1). Future research should attempt to elucidate the exact mechanisms that 
underlie the complex interaction between preeclampsia and kidney disease.
 
Figure 1: Proposed mechanisms.
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